Ensysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Commencing to Phase 2 clinical development
Covistat to present pre-clinical data at American Thoracic Society annual meeting, May 14-19, 2021
Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
NEW YORK and SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce”) and Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW) , a special purpose...
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
Additional Contract Broadens and Further Strengthens Customer Product Portfolio